Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 27

1.

Use of Cyclo-Oxygenase Inhibitors Is Not Associated with Clinical Relapse in Inflammatory Bowel Disease: A Case-Control Study.

Hensley A, Beales IL.

Pharmaceuticals (Basel). 2015 Sep 7;8(3):512-24. doi: 10.3390/ph8030512.

2.

Environmental triggers for inflammatory bowel disease.

Ananthakrishnan AN.

Curr Gastroenterol Rep. 2013 Jan;15(1):302. doi: 10.1007/s11894-012-0302-4. Review.

3.

Aspirin, nonsteroidal anti-inflammatory drug use, and risk for Crohn disease and ulcerative colitis: a cohort study.

Ananthakrishnan AN, Higuchi LM, Huang ES, Khalili H, Richter JM, Fuchs CS, Chan AT.

Ann Intern Med. 2012 Mar 6;156(5):350-9. doi: 10.7326/0003-4819-156-5-201203060-00007.

4.

Aspirin use and development of inflammatory bowel disease: confounding or causation?

Yi F, Xia B.

Aliment Pharmacol Ther. 2011 Dec;34(11-12):1350-1; author reply 1351. doi: 10.1111/j.1365-2036.2011.04872.x. No abstract available.

5.

Aspirin in the aetiology of Crohn's disease and ulcerative colitis: a European prospective cohort study.

Chan SS, Luben R, Bergmann MM, Boeing H, Olsen A, Tjonneland A, Overvad K, Kaaks R, Kennedy H, Khaw KT, Riboli E, Hart AR.

Aliment Pharmacol Ther. 2011 Sep;34(6):649-55. doi: 10.1111/j.1365-2036.2011.04784.x. Epub 2011 Jul 26.

6.

Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality?

Kefalakes H, Stylianides TJ, Amanakis G, Kolios G.

Eur J Clin Pharmacol. 2009 Oct;65(10):963-70. doi: 10.1007/s00228-009-0719-3. Epub 2009 Aug 27. Review.

PMID:
19711064
7.

Mud-bath treatment in spondylitis associated with inflammatory bowel disease--a pilot randomised clinical trial.

Cozzi F, Podswiadek M, Cardinale G, Oliviero F, Dani L, Sfriso P, Punzi L.

Joint Bone Spine. 2007 Oct;74(5):436-9. Epub 2007 May 30.

PMID:
17590368
8.

[Chronic inflammatory bowel diseases. Proven and innovative in the treatment].

[No authors listed]

MMW Fortschr Med. 2006 Jun 15;148(24):43. German. No abstract available.

PMID:
16850809
9.

Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease.

Takeuchi K, Smale S, Premchand P, Maiden L, Sherwood R, Thjodleifsson B, Bjornsson E, Bjarnason I.

Clin Gastroenterol Hepatol. 2006 Feb;4(2):196-202.

PMID:
16469680
10.

Significance of salicylate intolerance in diseases of the lower gastrointestinal tract.

Raithel M, Baenkler HW, Naegel A, Buchwald F, Schultis HW, Backhaus B, Kimpel S, Koch H, Mach K, Hahn EG, Konturek PC.

J Physiol Pharmacol. 2005 Sep;56 Suppl 5:89-102.

11.

Risk factors for inflammatory bowel disease in the general population.

García Rodríguez LA, González-Pérez A, Johansson S, Wallander MA.

Aliment Pharmacol Ther. 2005 Aug 15;22(4):309-15.

12.

5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study.

van Staa TP, Card T, Logan RF, Leufkens HG.

Gut. 2005 Nov;54(11):1573-8. Epub 2005 Jun 30. Review.

13.

[Inflammatory bowel disease--diagnosis and therapy].

Vogt W.

Praxis (Bern 1994). 2005 Feb 2;94(5):145-50. Review. German.

PMID:
15745379
14.

[Therapy of chronic inflammatory bowel diseases].

Stange EF.

Praxis (Bern 1994). 2002 Nov 20;91(47):2029-39. Review. German.

PMID:
12501498
15.

[Etiology and pathogenesis of inflammatory bowel diseases].

Schölmerich J.

Praxis (Bern 1994). 2002 Nov 20;91(47):2017-22. Review. German.

PMID:
12501496
16.

[Chronic inflammatory bowel diseases. Earlier transition to immunosuppressive drugs].

Bischoff A.

MMW Fortschr Med. 2002 May 2;144(18):10. German. No abstract available.

PMID:
12422699
17.
18.

Influence of treatment on morphological features of mucosal inflammation.

Geboes K, Dalle I.

Gut. 2002 May;50 Suppl 3:III37-42. Review.

19.

[Is the lung a target organ in inflammatory bowel disease?].

Marvisi M, Fornasari G.

Recenti Prog Med. 2001 Dec;92(12):774-7. Review. Italian.

PMID:
11822102
20.

Expression of platelet P-selectin and detection of soluble P-selectin, NPY and RANTES in patients with inflammatory bowel disease.

Fägerstam JP, Whiss PA, Ström M, Andersson RG.

Inflamm Res. 2000 Sep;49(9):466-72.

PMID:
11071121

Supplemental Content

Loading ...
Support Center